Top Clicks This Month

6-Quinoxalinecarbonitrile,1,2,3,4-tetrahydro-2-oxo-(9CI) - CAS 221290-03-5

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
Main Product
Product Name
6-Quinoxalinecarbonitrile,1,2,3,4-tetrahydro-2-oxo-(9CI)
Catalog Number
221290-03-5
Synonyms
2-oxo-3,4-dihydro-1H-quinoxaline-6-carbonitrile;221290-03-5;6-Quinoxalinecarbonitrile,1,2,3,4-tetrahydro-2-oxo-;2-OXO-1,2,3,4-TETRAHYDROQUINOXALINE-6-CARBONITRILE;SCHEMBL6618447;CTK4E8701
CAS Number
221290-03-5
Molecular Weight
173.17138;g/mol
Molecular Formula
C9 H7 N3 O
COA
Inquire
MSDS
Inquire
Canonical SMILES
C1C(=O)NC2=C(N1)C=C(C=C2)C#N
InChI
InChI=1S/C9H7N3O/c10-4-6-1-2-7-8(3-6)11-5-9(13)12-7/h1-3,11H,5H2,(H,12,13)
InChIKey
VCQBDEDRWMCMMN-UHFFFAOYSA-N
Structure
CAS 221290-03-5 6-Quinoxalinecarbonitrile,1,2,3,4-tetrahydro-2-oxo-(9CI)
Specification
Purity
95%
Reference Reading
1.High sensitivity analysis of water-soluble, cyanine dye labeled proteins by high-performance liquid chromatography with fluorescence detection.
Qiao X1, Wang L, Ma J, Deng Q, Liang Z, Zhang L, Peng X, Zhang Y. Anal Chim Acta. 2009 Apr 27;640(1-2):114-20. doi: 10.1016/j.aca.2009.03.021. Epub 2009 Mar 20.
A water-soluble sulfo-3H-indocyanine dye, the active N-hydroxysuccinimide ester of 3H-Indolium,1-[(4-carboxyphenyl)methyl]-2-[3-[1-[(4-carboxyphenyl)methyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1-propenyl]-3,3-dimethyl-5-sulfo-(9CI) (sb-cy3-NHS), containing two p-carboxybenzyl groups on nitrogen atoms, previously developed by our laboratory, was for the first time used for protein derivatization, followed by HPLC separation and fluorescence detection. With bovine serum albumin (BSA) as a model protein, effects of various experimental conditions, including denaturant concentration, reaction time and temperature, the pH value of buffer, and the molar ratio of fluorescence reagent to protein, on protein derivatization efficiency were systematically investigated. Under the optimal conditions, the limit of detection (LOD) for derivatized BSA was decreased to 12.8 nM, about 100-fold lower than that by UV and fluorescence detection with commercial fluorescein isothiocyanate (FITC) as labeling reagent.
2.Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).
National Toxicology Program. Natl Toxicol Program Genet Modif Model Rep. 2013 Oct;(16):1-236.
3'-Azido-3'-deoxythymidine (AZT) is the most widely used and evaluated chemotherapeutic agent for the treatment of persons with acquired immune deficiency syndrome (AIDS). Antiviral therapy is essential for treatment and prevention of AIDS in adults and children infected with human immunodeficiency virus (HIV), and to prevent mother-to-child transmission of HIV during pregnancy and labor. The studies described in this report were designed to determine possible long-term sequelae from AZT treatment, often used in combination with other antiviral drugs, such as lamivudine (3TC) and nevirapine (NVP) in preventing mother-to-child transmission of HIV. Male and female heterozygous F1 p53+/- mice were exposed to AZT, 3TC, NVP, or combinations of the chemicals in utero on gestation days (GD) 12 through 18, then administered the same chemical or combination of chemicals by gavage from postnatal day (PND) 1 through PND 28 and then observed until 45 weeks of age.
3.Toxicology and carcinogenesis of 3´-azido-3´-deoxythymidine (AZT) (CAS No. 30516-87-1) in genetically modified C3B6.129F1-Trp53(tm1Brd) N12 haploinsufficient mice (in utero and postnatal gavage studies).
National Toxicology Program. Natl Toxicol Program Genet Modif Model Rep. 2013 Oct;(14):1-200.
Antiviral therapy is essential for treatment and prevention of human immunodeficiency virus (HIV) disease in adults and children and to prevent mother-to-child transmission of HIV during pregnancy and labor. The studies described in this report were designed to determine possible long-term sequelae from 3´-azido-3´-deoxythymidine (AZT) treatment, often used in combination with other antivirals, in preventing mother-to-child transmission of HIV. AZT is the most widely used and evaluated chemotherapeutic agent for the treatment of persons with acquired immune deficiency syndrome (AIDS). Male and female heterozygous F1 p53+/- mice were exposed, by maternal gavage, to AZT in utero on gestation days (GD) 12 through 18, then administered AZT by gavage from postnatal day (PND) 1 through 30 weeks of age (30-week study), 45 weeks of age (45-week study), or PND 8 (45-week stop-study). Mice in the 0 mg/kg groups received only an aqueous solution containing 0.
4.Differential effects of the Gβ5-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release.
Karpinsky-Semper D1, Volmar CH, Brothers SP, Slepak VZ. Mol Pharmacol. 2014 May;85(5):758-68. doi: 10.1124/mol.114.091843. Epub 2014 Feb 28.
The G protein β subunit Gβ5 uniquely forms heterodimers with R7 family regulators of G protein signaling (RGS) proteins (RGS6, RGS7, RGS9, and RGS11) instead of Gγ. Although the Gβ5-RGS7 complex attenuates Ca(2+) signaling mediated by the muscarinic M3 receptor (M3R), the route of Ca(2+) entry (i.e., release from intracellular stores and/or influx across the plasma membrane) is unknown. Here, we show that, in addition to suppressing carbachol-stimulated Ca(2+) release, Gβ5-RGS7 enhanced Ca(2+) influx. This novel effect of Gβ5-RGS7 was blocked by nifedipine and 2-aminoethoxydiphenyl borate. Experiments with pertussis toxin, an RGS domain-deficient mutant of RGS7, and UBO-QIC {L-threonine,(3R)-N-acetyl-3-hydroxy-L-leucyl-(aR)-a-hydroxybenzenepropanoyl-2,3-idehydro-N-methylalanyl-L-alanyl-N-methyl-L-alanyl-(3R)-3-[[(2S,3R)-3-hydroxy-4- methyl-1-oxo-2-[(1-oxopropyl)amino]pentyl]oxy]-L-leucyl-N,O-dimethyl-,(7→1)-lactone (9CI)}, a novel inhibitor of Gq, showed that Gβ5-RGS7 modulated a Gq-mediated pathway.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE